Merakris Therapeutics, founded in 2016, is at the forefront of scientific advancement in regenerative medicine. Dedicated to championing a precision medicine approach to wound care, Merakris seeks to improve global patient care and outcomes with cell-free regenerative therapies. The company's flagship Dermacyte Amniotic Wound Care Matrix provides a protective barrier to cover wounds and soft tissue to facilitate faster and more effective healing of various wound types. Dermacyte Liquid, a subcutaneous cell-free human amniotic fluid injection for complex wound healing, is currently in Phase 2 clinical trials. The company also is investigating other novel biomedical solutions that promote wound healing and tissue regeneration.